Proteomic profiling identifies N-acetylmuramoyl-l-alanine amidase as a novel biomarker of sepsis.

Abstract

AIM:

Sepsis is a critical condition that leads to high mortality and is the most common cause of death in intensive care units. Despite exhaustive efforts by the scientific community, a reliable biomarker for diagnosis, evolution and prognosis of sepsis is still lacking. Results & methodology: Here, using high-throughput proteomics, we describe N-acetylmuramoyl-l-alanine amidase as a novel candidate for differentiating infectious and noninfectious inflammatory syndromes.

DISCUSSION & CONCLUSION:

This is the first description of N-acetylmuramoyl-l-alanine amidase as a biomarker that can be used alone or in conjunction with other biomarkers to facilitate the diagnosis of sepsis in the critically ill.

• Authors: Fabiano Pinheiro da Silva, Thais Regiani Cataldi, Thais Martins de Lima, Paulo Nogueira Starzynski, Hermes Vieira Barbeiro, Monica Teresa Veneziano Labate, Marcel Cerqueira Cesar CéMachado, Heraldo Possolo de Souza, Carlos Alberto Labate
• Journal: Biomarkers in medicine (Biomark Med) Vol. 10 Issue 12 Pg. 1225-1229 (Dec 2016) ISSN: 1752-0371 [Electronic] England
• PMID: 27911590 (Publication Type: Journal Article)

Chemical References

• Biomarkers
• C-Reactive Protein
• N-Acetylmuramoyl-L-alanine Amidase

Topics

• Biomarkers (blood)
• C-Reactive Protein (analysis)
• Case-Control Studies
• Chromatography, High Pressure Liquid
• Deuterium Exchange Measurement
• Humans
• Intensive Care Units
• Mass Spectrometry
• N-Acetylmuramoyl-L-alanine Amidase (blood)
• Proteomics
• Sepsis (diagnosis, pathology)